FDA Approves Respiratory Syncytial Virus Vaccine Under Priority Review Voucher Program

Summary

The FDA has approved MRESVIA (Respiratory Syncytial Virus Vaccine), a product redeeming a priority review voucher, following the issuance of a notice by the agency. The vaccine meets the criteria for redeeming a priority review voucher, as determined by the FDA.